Clinical trial
Epoetin Alfa in Treating Patients With Anemia Who Are Undergoing Chemotherapy…
NCT00255749 · Jonsson Comprehensive Cancer Center, Other · Completed
Key facts
| NCT number | NCT00255749 |
|---|---|
| Title | Epoetin Alfa in Treating Patients With Anemia Who Are Undergoing Chemotherapy for Cancer |
| Official title | Assessment of Early and Standard Intervention With Procrit® (Epoetin Alfa) 120,000 Units Once Every Three Weeks (Q3W) in Patients With Cancer Receiving Chemotherapy |
| Lead sponsor | Jonsson Comprehensive Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Anemia, Leukemia, Lymphoma, Lymphoproliferative Disorder, Multiple Myeloma and Plasma Cell Neoplasm, Precancerous Condition, Unspecified Adult Solid Tumor, Protocol Specific |
| Intervention type | Biological |
| Interventions | epoetin alfa |
| Enrollment | 89 |
| Start date | Aug 1, 2005 |
| Primary completion | Apr 1, 2007 |
| First posted | Nov 21, 2005 |
| Last update posted | Oct 4, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: